» Articles » PMID: 15164171

Diabetes Mellitus and Risk of Prostate Cancer: a Meta-analysis

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2004 May 28
PMID 15164171
Citations 103
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/hypothesis: The association of diabetes mellitus with prostate cancer has been controversial. This study examines the strength of this association by conducting a detailed meta-analysis of the studies published in peer-reviewed literature on the subject.

Methods: A comprehensive search for articles published up to 2003 was performed, reviews of each study were conducted and data were abstracted. Prior to meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) was calculated using the random- and the fixed-effects models. Subgroup and sensitivity analyses were also performed.

Results: We included 14 studies, published between 1971 and 2002, in the meta-analysis (five case-control studies, nine cohort studies). We found no evidence of publication bias ( p=0.89) or heterogeneity among the studies ( p=0.38). The association of diabetes with prostate cancer was statistically significant, both on the basis of a random-effects model (RR=0.91, 95% CI: 0.86 to 0.96), and on the basis of a fixed-effects model (RR=0.91, 95% CI: 0.88 to 0.94). When the analysis was stratified into subgroups according to study design, the association was inverse in both cohort and case-control studies, but only in the former was it statistically significant. The sensitivity analysis strengthened our confidence in the validity of this association.

Conclusions/interpretation: Our meta-analysis findings provide strong evidence that people with diabetes have a significant decrease in risk of developing prostate cancer. There is biological evidence to support this association.

Citing Articles

Diabetes Mellitus and Prostate Cancer Risk-A Systematic Review and Meta-Analysis.

Drab A, Wdowiak K, Kanadys W, Zajaczkowski K, Koczkodaj P, Religioni U Cancers (Basel). 2024; 16(23).

PMID: 39682196 PMC: 11640538. DOI: 10.3390/cancers16234010.


Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.

Sharma N, Khatib M, Balaraman A, Roopashree R, Kaur M, Srivastava M Int Urol Nephrol. 2024; 57(4):1039-1049.

PMID: 39495435 DOI: 10.1007/s11255-024-04266-4.


A Mendelian randomization study between metabolic syndrome and its components with prostate cancer.

Xia L, Yu X, Wang L, Yang L, Bao E, Wang B Sci Rep. 2024; 14(1):14338.

PMID: 38906920 PMC: 11192917. DOI: 10.1038/s41598-024-65310-y.


The association between diabetes mellitus and prostate cancer: a meta-analysis and Mendelian randomization.

Ye G, Yang Y, Luo K, Wang S, Xia Q Aging (Albany NY). 2024; 16(11):9584-9598.

PMID: 38836754 PMC: 11210264. DOI: 10.18632/aging.205886.


Metformin: A Dual-Role Player in Cancer Treatment and Prevention.

Galal M, Al-Rimawi M, Hajeer A, Dahman H, Alouch S, Aljada A Int J Mol Sci. 2024; 25(7).

PMID: 38612893 PMC: 11012626. DOI: 10.3390/ijms25074083.


References
1.
Lagergren J, Bergstrom R, Nyren O . Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999; 130(11):883-90. DOI: 10.7326/0003-4819-130-11-199906010-00003. View

2.
Everhart J, Wright D . Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995; 273(20):1605-9. View

3.
Friedenreich C, Brant R, Riboli E . Influence of methodologic factors in a pooled analysis of 13 case-control studies of colorectal cancer and dietary fiber. Epidemiology. 1994; 5(1):66-79. DOI: 10.1097/00001648-199401000-00011. View

4.
Talamini R, Franceschi S, La Vecchia C, Serraino D, Barra S, Negri E . Diet and prostatic cancer: a case-control study in northern Italy. Nutr Cancer. 1992; 18(3):277-86. DOI: 10.1080/01635589209514228. View

5.
Steenland K, Nowlin S, Palu S . Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomarkers Prev. 1995; 4(8):807-11. View